Evidence map›Paper›PMID 38872714›Full record

ArticleJAC-antimicrobial resistance2024

María García-Castillo, Marta Hernández-García, Adriana Correa, Marco Coppi, Thomas Griener, Thomas Fritsche, Cristina Pitart, Jorge Sampaio, Harald Seifert, Karen Wake and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAC-antimicrobial resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

María García-CastilloServicio de Microbiología, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Marta Hernández-GarcíaServicio de Microbiología, Hospital Universitario Ramón y Cajal, Madrid, Spain.ORCID https://orcid.org/0000-0003-2857-2572
Adriana CorreaClínica Imbanaco Grupo Quirón Salud, Cali, Valle del Cauca, Colombia.
Marco CoppiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.ORCID https://orcid.org/0000-0002-4387-4037
Thomas GrienerClinical Section of Microbiology, Alberta Precision Laboratories, Calgary, Alberta, Canada.
Thomas FritscheDivision of Laboratory Medicine, Marshfield Clinic Research Institute, Marshfield, WI, USA.
Cristina PitartCIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto Salud Carlos III, Madrid, Spain.
Jorge SampaioDepartment of Clinical and Toxicological Analyses, School of Pharmacy, University of São Paulo, São Paulo, Brazil.
Harald SeifertGerman Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0002-7732-4762
Karen WakeCanadian Antimicrobial Resistance Alliance, Health Sciences Centre University of Manitoba, Manitoba, Canada.
Mandy WoottonSpecialist Antimicrobial Chemotherapy Unit, Public Health Wales, University Hospital of Wales, Cardiff, UK.
Jordi VilaCIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto Salud Carlos III, Madrid, Spain.
Rafael CantónServicio de Microbiología, Hospital Universitario Ramón y Cajal, Madrid, Spain.ORCID https://orcid.org/0000-0003-1675-3173

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: We performed a multicentre study (2020-2022) to compare the Methods: A total of 1725 isolates (1454 Results: Ozenoxacin exhibited high Conclusions: Ozenoxacin is a potent antimicrobial agent of topic use against Gram-positive bacteria causing SSTI, including MRSA isolates non-susceptible to ciprofloxacin.

Identifiers

PMID38872714
PMCPMC11170484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.